Brain tumor trial combines radiation with targeted drugs and immunotherapy
NCT ID NCT04074096
First seen Apr 03, 2026 · Last updated Jun 17, 2026 · Updated 10 times
Summary
This study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific genetic mutation (BRAF V600). The goal is to see if the radiation helps prevent brain tumors from growing back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM - Hopital De La Timone
Marseille, France
-
APHP - Hôpital Ambroise Paré
Boulogne-Billancourt, France
-
APHP - Hôpital Avicenne
Bobigny, France
-
APHP - Hôpital Henri Mondor
Créteil, France
-
APHP - L'hôpital de la Pitié-Salpêtrière
Paris, France
-
CHU De Montpellier - Hopital Saint Eloi
Montpellier, France
-
CHU Nice - Hôpital de l'Archet
Nice, France
-
CHU de Bordeaux - Hôpital Saint André
Bordeaux, France
-
CHU de Caen
Caen, France
-
CHU de Dijon - Hopital Du Bocage
Dijon, France
-
CHU de Nantes - Hôtel Dieu
Saint-Herblain, France
-
CHU de TOURS - Hôpital Bretonneau
Tours, France
-
CLCC - Centre Antoine Lacassagne
Nice, France
-
CLCC - Centre Georges François Leclerc
Dijon, France
-
CLCC - Centre Jean François Baclesse
Caen, France
-
CLCC - Centre Léon Bérard
Lyon, France
-
CLCC - Gustave Roussy
Villejuif, France
-
CLCC - IUCT-0 / Institut Claudius Regaud
Toulouse, France
-
CLCC - Institut de Cancerologie de Montpellier
Montpellier, France
-
CLCC - Institut de Cancerologie de l'Ouest - Nantes
Saint-Herblain, France
-
GH Sud CHU Bordeaux - Hôpital Levêque
Bordeaux, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.